Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 11/20 | 0.93 |
| ▸ | LPAR2 | Q9HBW0 | 10/20 | 0.93 |
| ▸ | LPAR1 | Q92633 | 8/20 | 0.93 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.64 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.54 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.54 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.54 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.54 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TSPO | P30536 | 1/20 | 0.54 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18123889 | 1.00 | LPAR3 (0.93) | LPAR3LPAR2LPAR1ENPP2S1PR4 | |
| SCHEMBL304775 | 1.00 | LPAR3 (0.93) | LPAR3LPAR2LPAR1ENPP2S1PR4 | |
| SCHEMBL4981337 | 1.00 | LPAR3 (0.93) | LPAR3LPAR2LPAR1ENPP2S1PR4 | |
| SCHEMBL19821294 | 1.00 | LPAR3 (0.93) | LPAR3LPAR2LPAR1ENPP2S1PR4 | |
| SCHEMBL7781151 | 1.00 | LPAR3 (0.93) | LPAR3LPAR2LPAR1ENPP2S1PR4 | |
| SCHEMBL23016698 | 1.00 | LPAR3 (0.93) | LPAR3LPAR2LPAR1ENPP2S1PR4 | |
| SCHEMBL4981351 | 1.00 | LPAR3 (0.93) | LPAR3LPAR2LPAR1ENPP2S1PR4 | |
| SCHEMBL38660089 | 1.00 | LPAR3 (0.93) | LPAR3LPAR2LPAR1ENPP2S1PR4 | |
| SCHEMBL193119 | 1.00 | LPAR3 (0.93) | LPAR3LPAR2LPAR1ENPP2S1PR4 | |
| SCHEMBL11757308 | 0.98 | LPAR3 (0.90) | LPAR3LPAR2LPAR1ENPP2S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117441047-A | Treatment agent for synthetic fibers, and method for treating synthetic fibers | 竹本油脂株式会社 | 2024-01-23 | — | — | CN | disclosed |
| CN-112111314-B | Surface protective agent composition and covered wire with terminal | 株式会社自动网络技术研究所 | 2022-08-30 | — | — | CN | disclosed |
| CN-114144187-A | Lipid nanoparticles containing pharmaceutical and/or nutraceutical agents and methods thereof | 德克萨斯大学系统董事会 | 2022-03-04 | — | — | CN | disclosed |
| CN-110952319-B | Treating agent for synthetic fiber and method for producing synthetic fiber | 竹本油脂株式会社 | 2021-01-22 | — | — | CN | disclosed |
| CN-110952319-A | Treating agent for synthetic fiber and method for producing synthetic fiber | 竹本油脂株式会社 | 2020-04-03 | — | — | CN | disclosed |
| CN-106573840-A | Admixture for hydraulic composition | 东邦化学工业株式会社 | 2017-04-19 | — | — | CN | disclosed |
| EP-2481743-B1 | LPA receptor agonists and antagonists and methods of use | UNIV TENNESSEE RES FOUND (US) | 2017-03-22 | — | — | EP | disclosed |
| EP-2433946-B1 | LPA receptor agonists and antagonists and methods of use | UNIV TENNESSEE RES FOUNDATION (US) | 2016-04-20 | — | — | EP | disclosed |
| EP-2767541-A1 | LPA receptor agonists and antagonists | Rxbio, Inc. (US) | 2014-08-20 | — | — | EP | disclosed |
| EP-2262371-B1 | LPA RECEPTOR AGONISTS AND ANTAGONISTS | RXBIO INC (US) | 2014-01-01 | — | — | EP | disclosed |
| EP-2262371-A1 | LPA RECEPTOR AGONISTS AND ANTAGONISTS | Rxbio, Inc. (US) | 2010-12-22 | — | — | EP | disclosed |
| WO-2010051053-A1 | LPA RECEPTOR AGONISTS AND ANTAGONISTS | RXBIO, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
| CN-100471927-C | Improved drilling fluids | ICI PLC (GB) | 2009-03-25 | — | — | CN | disclosed |
| US-20080090783-A1 | lysophosphatidic acid receptor modulator; thiophosphoric acid O-[7-(4-octyl-phenyl)-heptyl] ester; treating cancer, wounds, skin disorders and apoptosis; preserving or restoring function in a cell, tissue or organ; culturing cells; preserving organ or tissue function; and enhancing cell proliferation | MILLER DUANE D | 2008-04-17 | — | — | US | disclosed |
| US-7217704-B2 | LPA receptor agonists and antagonists and methods of use | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2007-05-15 | — | — | US | disclosed |
| EP-1678096-A4 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | UNIV TENNESSEE RES CORP (US) | 2007-04-18 | — | — | EP | disclosed |
| CN-1930265-A | Improved drilling fluids | ICI PLC (GB) | 2007-03-14 | — | — | CN | disclosed |
| EP-1678096-A2 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20060009507-A1 | Thio-phosphoric and -phosphorous acid derivatives; treating cancer, wounds, skin disorders and apoptosis; preserving or restoring function in a cell, tissue or organ; culturing cells; preserving organ or tissue function; and enhancing cell proliferation | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2006-01-12 | — | — | US | disclosed |
| WO-2005032494-A2 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009507-A1 | Thio-phosphoric and -phosphorous acid derivatives; treating cancer, wounds, skin disorders and apoptosis; preserving or restoring function in a cell, tissue or organ; culturing cells; preserving organ or tissue function; and enhancing cell proliferation | LPAR1, LPAR6, LPAR2 | LPAR3 6/4885LPAR2 3/4885LPAR1 1/4885 |
| US-20080090783-A1 | lysophosphatidic acid receptor modulator; thiophosphoric acid O-[7-(4-octyl-phenyl)-heptyl] ester; treating cancer, wounds, skin disorders and apoptosis; preserving or restoring function in a cell, tissue or organ; culturing cells; preserving organ or tissue function; and enhancing cell proliferation | LPAR1, LPAR4, LPAR2 | LPAR3 6/4885LPAR2 3/4885LPAR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.